 Item 2.02 Results of Operations and Financial Condition. 

Although it has not finalized its full financial results for the quarter ended June 30, 2023, Vir Biotechnology, Inc. (the “Company”) disclosed in a press release on July 20, 2023, that it had cash, cash equivalents and investments of approximately $1.9 billion as of June 30, 2023. 

The information contained in Item 2.02 of this Form 8-K regarding the Company’s cash balance as of June 30, 2023, is preliminary and is subject to completion of the Company’s financial closing procedures. This cash figure does not present all information necessary for an understanding of the Company’s financial condition as of June 30, 2023, and its results of operations for the three and six months ended June 30, 2023. The Company’s independent registered public accounting firm has not conducted a review of and does not express an opinion or any other form of assurance with respect to, the cash figure. 

The information in this Item 2.02, including the attached Exhibit 99.1, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing. 

 

